Notice of Proposed Sale · 144
Tenaya Therapeutics, Inc.
TNYANASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Tenaya Therapeutics, Inc.
- Issuer CIK
- 0001858848
- SEC file number
- 001-40656
- Phone
- (650)-825-6990
- Person for whose account securities are to be sold
- Faraz Ali
- Relationships to issuer
- Officer · Director
- Street
- 171 Oyster Point Boulevard
- Street (continued)
- Suite 500
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 22,232 | 15,778.45 | 224,230,012 | 08/17/2026 | Nasdaq Capital Mkt | Morgan Stanley Smith Barney |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney
- Street
- Operations Department
- Street (continued)
- 2000 Westchester Ave
- City
- Purchase
- State / country code
- NY
- Postal code
- 10577-2530
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 08/17/2026 | Restricted Stock Unit | Issuer | 59,512 | N | 08/17/2026 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/17/2026
- Signed
- /s/ Faraz Ali
Company context
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.